SpyGlass Pharma, Inc.
SpyGlass Pharma (Nasdaq: SGP) is a late-stage biopharmaceutical company developing sustained-release drug delivery systems for chronic eye conditions. Its lead candidate, the Bimatoprost Drug Pad-IOL System, attaches drug pads to an intraocular lens and is designed to release bimatoprost for three years to reduce… From the company’s description.
In fiscal 2025, SpyGlass Pharma, Inc. reported a net loss of $39.87M. Operations used $32.70M in cash.
Dotted labels explain each measure.
What SpyGlass Pharma, Inc. does
In the company’s own words
SpyGlass Pharma (Nasdaq: SGP) is a late-stage biopharmaceutical company developing sustained-release drug delivery systems for chronic eye conditions. Its lead candidate, the Bimatoprost Drug Pad-IOL System, attaches drug pads to an intraocular lens and is designed to release bimatoprost for three years to reduce elevated eye pressure in patients with open-angle glaucoma or ocular hypertension during cataract surgery. The company is also developing a removable, ring-shaped bimatoprost implant for standalone use and retreatment, and is assessing its platform for other eye conditions. SpyGlass’s SpyGlass Platform is designed to deliver established medicines through implantable systems, including its lens-mounted Drug Pad-IOL System and non-IOL Drug Ring System. Founded in 2019, the company retains worldwide development and commercialization rights to its programs. Its two registrational Phase 3 trials for the lead candidate began in 2025. SpyGlass has no approved commercial products described in its business overview. Its website is not stated.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1778922
- SIC
- 3841
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SpyGlass Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SpyGlass Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SpyGlass Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SpyGlass Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SpyGlass Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”